The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 6, 2002, Pages 509-513

  Schroeder, Patricia E ^a   Hasinoff, Brian B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

ADR 925; Antioxidant; Dexrazoxane; Doxorubicin; Iron

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; CASEIN; DOXORUBICIN; IRON; METAL CHELATE; METAL ION; OXYGEN RADICAL; RAZOXANE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG UPTAKE; ENZYME ACTIVITY; FLOW INJECTION ANALYSIS; HEART; HEART PROTECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; REACTION ANALYSIS;

ANIMALS; BIOTRANSFORMATION; CARDIOVASCULAR AGENTS; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ETHYLENEDIAMINES; FLUORESCEINS; GLYCINE; HALF-LIFE; INDICATORS AND REAGENTS; INFUSIONS, INTRAVENOUS; IRON; MALE; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RAZOXANE;

EID: 0036449366     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0538-z     Document Type: Article

References (31)

1. Buss JL, Hasinoff BB (1993) The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 40:86-95
2. Buss JL, Hasinoff BB (1997) Metal ion-promoted hydrolysis of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and its one-ring open hydrolysis products to its metal-chelating active form. J Inorg Biochem 68:101-108
3. Dawson KM (1975) Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21 S cells. Biochem Pharmacol 24:2249-2253
4. Diop NK, Vitellaro LK, Arnold P, Shang M, Marusak RA (2000) Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: Solid state structure, solution thermodynamics, and DNA cleavage activity. J Inorg Biochem 78:209-216
5. Durken M, Herrnring C, Finckh B, Nagel S, Nielsen P, Fischer R, Berger HM, Moison RM, Pichlmeier U, Kohlschutter B, Zander AR, Kohlschutter A (2000) Impaired plasma antioxidative defense and increased nontransferrin- bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Radic Biol Med 28:887-894
6. Gianni L, Zweier JL, Levy A, Myers CE (1985) Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen. J Biol Chem 260:6820-6826
7. Hasinoff BB (1989) The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane), its hydrolysis product ICRF-198, and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 26:378-385
8. Hasinoff BB (1989) Self-reduction of the iron(III)-doxorubicin complex. Free Radic Biol Med 7:583-593
9. Hasinoff BB (1990) The hydrolysis-activation of the doxorubicin cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxo-piperazinyl-1-yl)propane). Drug Metab Dispos 18:344-349
10. 3+-doxorubicin complex undergoing self-reduction by its α-ketol group. Biochem Cell Biol 68:1331-1336
11. Hasinoff BB (1993) Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab Dispos 21:883-888
12. Hasinoff BB (1994) An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates. Int J Pharm 107:67-76
13. Hasinoff BB (1994) Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J Pharm Sci 83:64-67
14. Hasinoff BB (1994) Stereoselective hydrolysis of ICRF-187 (dexrazoxane) and ICRF-186 by dihydropyrimidine amidohydrolase. Chirality 6:213-215
15. Hasinoff BB (1998) Chemistry of dexrazoxane and analogues. Semin Oncol 25 [Suppl. 10]:3-9
16. Hasinoff BB, Aoyama RG (1999) Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat. Drug Metab Dispos 27:265-268
17. Hasinoff BB, Aoyama RG (1999) Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). Chirality 11:286-290
18. Hasinoff BB, Reinders FX, Clark V (1991) The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. Drug Metab Dispos 19:74-80
19. Hasinoff BB, Venkataram S, Singh M, Kuschak TI (1994) Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica 24:977-987
20. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ (1998) Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5:1-28
21. Herman EH, Ferrans VJ (1993) Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother Pharmacol 32:445-449
22. Herman EH, Ferrans VJ (1998) Preclinical animal models of cardiac protection from anthracycline induced cardiotoxicity. Semin Oncol 25 [Suppl. 10]:15-21
23. Herman EH, El-Hage AN, Ferrans VJ, Witiak DT (1983) Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters. Res Commun Chem Pathol Pharmacol 40:217-231
24. Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, Green M, Blum RH, Speyer JL (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84:1725-1730
25. Huang Z-X, May PM, Quinlan KM, Williams DR, Creighton AM (1982) Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 12:536-542
26. Kendall DA, MacDonald RC (1983) Characterization of a fluorescence assay to monitor changes in the aqueous volume of lipid vesicles. Anal Biochem 134:26-33
27. Malisza KL, Hasino3 BB (1995) Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch Biochem Biophys 321:51-60
28. Myers C (1998) The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25:10-14
29. Sadée W, Staroscik J, Finn C, Cohen J (1975) Determination of (±)-1,2-bis(3,5-dioxopiperazinyl)propane plasma levels in rats, rabbits, and humans by glc and mass fragmentography. J Pharm Sci 64:998-1001
30. Swain SM, Whaley F, Gerber MC, Ewer MS, Bianchine JR, Gams RA (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333-1340
31. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332